Galectin Therapeutics Highlights Significant Research at AASLD 2024
NORCROSS, Ga. — Galectin Therapeutics, Inc. (NASDAQ: GALT), a pioneer in the development of innovative therapeutics targeting galectin proteins, has made a noteworthy announcement regarding its participation in the 2024 Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD). Three significant abstracts detailing ongoing Phase 2b/3 research trials are set to be presented, with a focus on conditions like MASH cirrhosis and portal hypertension.
Spotlight on Poster Presentations
The upcoming poster presentation session is scheduled for November 18, where these three crucial abstracts will be showcased in the “Portal Hypertension and Other Complications of Cirrhosis” segment. The research aims to shed light on essential clinical data that could shape future treatment protocols for patients battling chronic liver disorders.
In-Depth Abstract Insights
One of the abstracts titled "Evaluation of esophageal and gastric varices in cirrhotic patients with portal hypertension: a central evaluation system for clinical research," will be presented by Dr. Naim Alkhouri from Arizona Liver Health. This research aims to address the complexities surrounding the diagnosis and management of varices in patients suffering from cirrhosis.
Another noteworthy presentation from the NAVIGATE trial will feature baseline characteristics of the trial participants. Dr. Khurram Jamil, the Chief Medical Officer of Galectin Therapeutics, will lead this presentation which focuses on uncovering critical patient data sets that predict treatment outcomes.
The third abstract will discuss findings on patients with compensated MASH cirrhosis. Presented by Dr. Laura Ladron deGuevar from CIAID, this vital research notes that a significant portion of patients with portal hypertension may have undiagnosed esophageal varices, emphasizing the need for meticulous screening and management in this demographics.
Commitment to Liver Disease Solutions
Galectin Therapeutics is steadfast in its mission to develop groundbreaking therapies aimed at improving the quality of life for those afflicted with chronic liver diseases such as MASH. Their lead drug, belapectin, represents a carbohydrate-based approach to inhibit galectin-3 protein, which plays a crucial role in the progression of various fibrotic and inflammatory conditions.
This novel therapy has been granted Fast Track designation by the U.S. Food and Drug Administration, indicating its potential to address critical medical needs, especially for patients facing severe forms of liver ailments. The company is focusing its efforts on the critical treatment landscape of MASH-related fibrosis and utilized their unique expertise to streamline development processes via potential partnerships.
Future Directions for Galectin Therapeutics
In addition to their commitments in the liver disease sphere, Galectin Therapeutics is launching additional initiatives, exploring combination immunotherapies for advanced head and neck cancers and other malignancies. These projects reflect an expansive vision beyond liver health, showcasing the firm’s dedication to harnessing its scientific insights across various therapeutic areas.
As Galectin Therapeutics embarks on these innovative explorations, the importance of collaboration with strategic partners cannot be understated. The company aims to leverage their extensive experience in therapeutic development to ensure efficient and cost-effective advancement of their clinical programs.
Access to Research and Data
For attendees of the AASLD meeting, the abstracts will be accessible on the AASLD website. Furthermore, they will be featured in the October supplement of the esteemed journal Hepatology, making this information widely available for those interested in liver disease research.
Company Contact Information
For inquiries regarding the research and presentations, Galectin Therapeutics provides contact details:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investor Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What will Galectin Therapeutics present at the AASLD 2024?
Galectin Therapeutics will present three abstracts from their NAVIGATE trial focused on MASH cirrhosis and portal hypertension.
How is belapectin beneficial for liver diseases?
Belapectin targets the galectin-3 protein, potentially reducing inflammation and fibrosis in patients with chronic liver diseases.
What is the significance of the AASLD meeting?
The AASLD meeting is a key platform for discussing advancements in liver disease research and therapies, connecting researchers and healthcare professionals.
Who are the presenters of these abstracts?
Notable presenters include Dr. Naim Alkhouri, Dr. Khurram Jamil, and Dr. Laura Ladron deGuevar, who will provide insights into their research findings.
How can I find more information about Galectin Therapeutics?
More information can be found on their official website, where updates on their research and therapeutic developments are regularly posted.
